Spinal Concepts Warned Over QSR Violations, Unverified Design Changes
This article was originally published in The Gray Sheet
Abbott is in the process of integrating wholly-owned subsidiary Spinal Concepts into its quality systems program in order to assure a more systematic approach and greater level of compliance with FDA, according to company reps
You may also be interested in...
FDA's Orthopaedic & Rehabilitation Devices Panel will meet June 2 to review a PMA for Johnson & Johnson/DePuy's Charité artificial lumbar disc for degenerative disc disease
Abbott Labs will begin U.S. commercialization of its Prism, Architect and AxSYM full diagnostic assay menus over the next 12 months, following FDA's decision to end a four-year prohibition of product sales
Abbott Labs' entry into the orthopedics market through the $170 mil. purchase of Spinal Concepts mirrors its cardiovascular devices business strategy, according to the firm